FindTrial
Sign In

Oxacillin

DRUG5 trials

Sponsors

Assistance Publique Hopitaux De Paris, Pfizer, Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

BacteremiaBacterial InfectionsCatheter related bloodstream infections due to Staphylococcus aureusGram-Positive Bacterial InfectionsMethicillin-Resistant Staphylococcus AureusOsteomyelitisStaphylococcal BacteraemiaStaphylococcal Skin Infections

Phase 2

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
CompletedNCT00428844
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Osteomyelitis
Start: 2007-06-26End: 2010-06-23Updated: 2018-01-31
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
CompletedNCT04775953
National Institute of Allergy and Infectious Diseases (NIAID)Staphylococcal Bacteraemia
Start: 2021-04-22End: 2023-12-01Updated: 2024-12-10

Phase 3

Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
CompletedNCT00037050
PfizerBacteremia, Bacterial Infections, Gram-Positive Bacterial Infections
Start: 2002-04-30End: 2005-07-31Updated: 2009-09-14
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
CompletedNCT02814916
AbbVieBacterial Infections, Methicillin-Resistant Staphylococcus Aureus, Staphylococcal Skin Infections
Start: 2017-03-30End: 2024-01-01Updated: 2024-09-19
Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterrelated bloodstream infections due to Staphylococcus aureus [DALICATH]
RecruitingCTIS2024-514952-34-00
Assistance Publique Hopitaux De ParisCatheter related bloodstream infections due to Staphylococcus aureus
Start: 2023-06-23Target: 406Updated: 2025-04-23

Related Papers

Dalbavancin for Treatment of <i>Staphylococcus aureus</i> Bacteremia
JAMA2025-08-1317 citations
Substance use disorder-associated infections’ treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) – an investigator-initiated single-arm unblinded prospective cohort study
Therapeutic Advances in Infectious Disease2024-01-011 citations
The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections
The Pediatric Infectious Disease Journal2022-12-0719 citations
998. Clinical Outcomes and Cost Savings of Dalbavancin Use in OPAT: Focus on Complicated <i>Staphylococcus aureus</i> Infections
Open Forum Infectious Diseases2022-12-011 citations
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
Trials2022-05-1650 citations
Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
2021-12-146 citations